Recognizing this regulatory "blind spot," Dr. Tanaka and his colleagues, Yasumitsu Ogra and Sana Hasegawa, sought to create a comprehensive evaluation system. The team achieved this by combining two highly specialized technologies: asymmetric flow field-flow fractionation (AF4) and inductively coupled plasma mass spectrometry (ICP-MS). While both technologies have existed for some time, the Chiba University team utilized them in a novel configuration that allows for unprecedented precision in sorting and measuring particles.
The AF4 system serves as the separation engine of the process. Unlike traditional filtration or chromatography, AF4 uses a channel where particles are subjected to opposing liquid flows. In this study, the researchers utilized a specific "focus step" at the beginning of the process. During this stage, the sample is held within the AF4 channel while a "cross-flow" is applied across a special permeable membrane. This membrane acts as a molecular sieve, allowing only the tiniest dissolved particles—the free metal ions—to pass through. By comparing the signals from the mass spectrometer when this focus step is active versus when it is not, the researchers can precisely calculate the concentration of ions in the sample.
Once the ions are accounted for, the system proceeds to the standard AF4 separation process, which sorts the remaining solid particles by size. Larger particles move differently within the flow than smaller ones, allowing the system to "elute" or release them in a predictable order. As these sorted particles exit the AF4 system, they are fed directly into the ICP-MS device. This device acts as a high-sensitivity detector, vaporizing the particles and measuring the mass of the metallic elements within them. This tandem approach allows the researchers to create a detailed "profile" of the medication, showing exactly how much of the metal is ionic, how much is in the form of active nanoparticles, and how much has formed into aggregates.
To prove the practical utility of their method, the team applied it to Resovist, a well-known nanomedicine used as a contrast agent for liver magnetic resonance imaging (MRI). Resovist relies on iron oxide nanoparticles to enhance the clarity of scans. When the researchers analyzed the product using their new technique, the results were highly illuminating. They found that only 0.022% of the total iron in Resovist existed in an ionic form. This concentration, roughly 6.3 micrograms per milliliter, is exceptionally low and falls well within the safety margins for human use.
Furthermore, the analysis confirmed that the active iron nanoparticles in Resovist were consistently smaller than 30 nanometers in diameter. While some small aggregates of around 50 nanometers were detected, the researchers found no evidence of large, dangerous clumps. These findings not only validated the safety and stability of Resovist but also demonstrated that the new analytical method could provide the high-resolution data necessary for rigorous quality control.
